Journal of Bone Oncology 27 (2021) 100353

Contents lists available at ScienceDirect

Journal of Bone Oncology

journal homepage: www.elsevier.com/locate/jbo

Suicide and accidental deaths among patients with primary malignant bone tumors



^a Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

^b Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

^c Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

ARTICLE INFO

Research Paper

Article history: Received 21 December 2020 Revised 9 February 2021 Accepted 5 March 2021 Available online 18 March 2021

Keywords: Malignant bone tumors Amputation Psychological disorders Suicide

ABSTRACT

Background: It has been recognized that cancer is associated with a higher risk of suicide or accidental death. Earlier studies have evidenced that patients with malignant bone tumors usually experience psychological dysfunction and physical disability following surgery, which are shared risk factors between suicidal and accidental deaths. To our knowledge, there is no large population-based study on the risk of suicide or accidental death among patients with malignant bone tumors.

Questions/purposes: This study aimed to determine whether patients with primary malignant bone tumors are at a higher risk of suicide and accidental death than the general population and to identify the demographic and tumour-related characteristics and type of surgery associated with a higher risk of suicide and accidental death among these patients.

Methods: Overall, 50,817 patients diagnosed with primary malignant bone tumors between 1973 and 1975 were identified from the Surveillance, Epidemiology, and End Results database. The standardised mortality ratio (SMR) was calculated based on the general population's mortality data, gathered by the National Center for Health Statistics. The Cox regression model was developed to determine risk factors associated with a higher risk of suicide and accidental death.

Results: Patients with primary malignant bone tumors had a higher risk of suicide and accidental death than the general population in the United States (US) (SMR = 2.17; 95% confidence interval (CI) [1.80–2.62] and SMR = 1.73; 95% CI [1.54–1.95]). Compared with limb salvage, amputation significantly increased the risk of suicide (SMR = 3.99; 95% CI [2.52–6.34], hazard ratio (HR) = 2.32; 95% CI [1.31–4.09]; P < 0.01) but did not increase the risk of accidental death (SMR = 1.61; 95% CI [1.07–2.42], HR = 1.11; 95% CI [0.71–1.74]; P = 0.65). Higher suicide risk was observed among older patients whose age at diagnosis was more than 60 years (HR = 4.04; 95% CI [1.98–8.26]; P < 0.001), males (HR = 3.48; 95% CI [2.16–5.62]; P < 0.001), and whites (HR = 3.71; 95% CI [1.17–11.73]; P < 0.001). The risk of suicide and accidental death was highest in the first year after diagnosis (SMR = 2.95; 95% CI [1.86–4.69] and SMR = 2.02; 95% CI [1.48–2.74]).

Conclusion: We first reported that patients with primary malignant bone tumors had a higher risk of suicide and accidental death than the general US population. Therefore, clinicians should pay more attention to the psychological status, physical function, and cognitive level of these survivors.

© 2021 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Suicide and accidental deaths are a global phenomenon that occurs throughout the lifespan [1]. In 2016, suicide was the 10th

leading cause of death in the United States (US) and the second leading cause of death among 15–29 year olds worldwide [2,3]. An estimated 800,000 people die from suicide every year globally [3]. Accidents were the third leading cause of death in the US, accounting for approximately 6% of all deaths, and it is estimated that 160,000 people die from accidents every year [2]. Cancer is associated with a higher risk of suicide or accidental death [1,4], and the risk has continued to increase during recent decades [1,5]. The common contributory factors between suicide and accidental death include psychological illnesses such as depression and









2212-1374/© 2021 Published by Elsevier GmbH.

^{*} Corresponding author at: Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.

E-mail address: lifengmd@hust.edu.cn (F. Li).

¹ Kaixu Yu and Bian Wu contributed equally to this work.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

anxiety, physical disability, poor quality of life, and social dysfunction [6].

Among patients with malignant bone tumors, changes in gait, function, stability, strength, and appearance have been observed and are related to disease and treatment [7,8]. The change from being a healthy individual to becoming a disabled person creates a new identity; it takes a long time for patients with bone tumors to accept this new identity [8]. During this process of shift, patients with bone tumors often experience serious psychological distress and problems in social life [9,10], which has been proven to increase the risk of suicide and accidental death [6,11–13]. Furthermore, higher levels of depression and anxiety have been shown in cancer survivors with amputation, especially within the first 2 years after amputation [14,15].

Stephanie et al. found a relative risk of nearly twice for suicide among cancer patients compared with the general US population [4]. Camidge et al. reported that, in Scottish, the risk of accidental death in cancer patients was 1.58 times that in the general population [16]. However, none of these reports on the risk of suicide or accidental death among cancer patients has isolated bone tumors as a single subgroup. To the best of our knowledge, currently, there is no large population-based study on the risk of suicide or accidental death among patients with malignant bone tumors. Therefore, the objectives of this study were to evaluate the risk of suicide and accidental death among patients with malignant bone tumors relative to that in the general population and to identify the characteristics linked to a higher risk of suicide and accidental death.

2. Patients and methods

This retrospective cohort study identified patients diagnosed with malignant bone tumors between January 1, 1973, and December 31, 2017, from the Surveillance, Epidemiology, and End Results (SEER) database established by the National Cancer Institute, which covered approximately 28% of the US population [17]. For comparison, the mortality data of the general US population collected by the National Center for Health Statistics spanning from 1969 to 2017 was used.

To exclude the impact of a secondary tumour on suicide or accidental death, we only included patients diagnosed with the first primary malignant bone tumors in this study, and those who had no age at diagnosis and survival time data were excluded. All patients were divided into seven subgroups according to the primary site of bone tumour, including the upper limb, lower limb, skull and face, vertebral column, thorax, pelvis, and others (specific primary site codes are listed in Table 1).

We extracted the demographic characteristics from the SEER database comprising age at diagnosis (0–14, 15–29, 30–44, 45–59, and 60 +), sex (female, male), race (white, black, and other), and calendar year of diagnosis (1973–1984, 1985–1995, 1996–2006, and 2007–2017). The tumour-related variables comprised the primary site and clinical stage of bone tumors (local, regional, distant, and unknown). All bone tumors were classified according to the International Classification of Disease for Oncology third revision (ICD-O-3) into five subtypes, including osteosarcoma, chondrosarcoma, Ewing sarcoma, chordoma, and others (ICD-O-3 codes are listed in Table 1). The surgery of bone tumors was categorised into "amputation", "limb salvage", "surgery, not otherwise specified (NOS)", "none", and "unknown". Survival time and cause of death were also available.

Patients with a cause of death coded as "Suicide and Self-Inflicted Injury (50220)" were considered to have committed suicide, and those with a cause of death coded as "Accidents and Adverse Effects (50210)" were considered to have died from accidents.

The number of suicides or accidental deaths divided by personyears of survival was calculated as the rate of suicide or accidental death. The data of patients with bone tumors were compared with those of the general population with similar distributions of age, sex, and race. Among cancer patient subgroups stratified by different characteristics, the standardised mortality ratios (SMRs) and 95% confidence intervals (95% CIs) were computed as described earlier [18]. Five-year age ranges were used for standardisation. To determine the demographic and tumour-related characteristics and type of surgery that was associated with a higher risk of suicide and accidental death, we developed a multivariate Cox proportional hazards model. Observations were censored if patients did not die from suicide or accidents at the time of the last follow-up. Survival time recorded as 0 months in the SEER database was converted to one-half of a month according to accepted epidemiologic practices [18].

All statistical tests were two-sided, and the values with P < 0.05 were considered statistically significant. The analysis was performed using the SEER*Stat software version 8.3.6 and the R version 3.51 statistical software.

3. Results

The analysed data revealed that a total of 108 suicides and 266 accidental deaths occurred among 50,817 patients with bone tumors, followed by 396,791 person-years. The suicide rate was 27.22/100,000 person-years, and the rate of accidental death was 67.04/100,000 person-years among cancer patients (Table 1). Patients with primary malignant bone tumors had a significantly higher risk of suicide and accidental death than the general US population with the same distribution of age, sex, and race (SMR = 2.17; 95% CI [1.80–2.62] and SMR = 1.73; 95% CI [1.54–1.95]). The survival time ranged from 0 to 42.92 years, with a mean survival time of 7.80 years.

3.1. Subgroups of patients with malignant bone tumors related to a higher risk of suicide and accidental death

There were 12 suicides and 54 accidental deaths observed among patients with malignant bone tumors whose age at diagnosis was less than 15 years old Fig. 1 and 2. These children with bone tumors had a higher risk of suicide and accidental death than the matched general population (SMR = 16.54; 95% CI [9.39-29.12] and SMR = 6.18; 95% CI [4.74–8.07]) (Figure 3). The old patients had a higher risk of suicide and accidental death among all age subgroups (SMR = 2.84; 95% CI [1.92-4.21] and SMR = 1.77; 95% CI [1.37–2.29]). Males had a higher risk of suicide and accidental death than the females (SMR = 2.17; 95% CI [1.76-2.67] and SMR = 2.19; 95% CI [1.43-3.36]). Patients with regional bone tumors and those with localised bone tumors were both equally likely to die from suicide (SMR = 2.61; 95% CI [1.96-3.48] and SMR = 2.06; 95% CI [1.55-2.74]) and accidents (SMR = 1.68; 95% CI [1.37-2.06] and SMR = 1.79; 95% CI [1.50-2.14]). The risk of suicide and accidental death for patients with advanced bone tumors was equal to that of the general population (SMR = 1.12; 95% CI [0.42-2.97] and SMR = 1.47; 95% CI [0.92-2.33]).

3.2. Sites of malignant bone tumors associated with a higher risk of suicide and accidental death

The suicide risk was the highest in patients with malignant bone tumors of the pelvic (32.90/100,000 person-years;



Suicide Risk by Age at Diagnosis







Fig. 2. The y-axis represented the absolute or relative number of suicides and the x-axis represented the age group at diagnosis. The colors depicted the histological subtypes of malignant bone tumors.



Fig. 3. The y-axis represented the absolute or relative number of accident deaths and the x-axis represented the age group at diagnosis. The colors depicted the histological subtypes of malignant bone tumors.

SMR = 2.11; 95% CI [1.27–3.50]), followed by those with lower limb bone tumors (29.87/100,000 person-years; SMR = 2.79; 95% CI [2.14–3.64]) and upper limb (28.85/100,000 person-years; SMR = 2.35; 95% CI [1.44–3.83]). The highest risk of accidental death was observed in patients with bone tumors of the vertebral column (148.17/100,000 person-years; SMR = 3.50; 95% CI [2.49– 4.93]), followed by those with bone tumors of the skull and face (111.35/100,000 person-years; SMR = 2.66; 95% CI [2.05–3.44]) and pelvic (85.55/100,000 person-years; SMR = 1.88; 95% CI [1.37–2.57]).



Fig. 4. Kaplan-Meier survival curve for suicide among patients with malignant bone tumors. The result of log-rank indicated that there was significant difference of risk of suicide between patients who underwent amputation and those who underwent limb salvage.

3.3. Pathological types of malignant bone tumors associated with a higher risk of suicide and accidental death

Among patients with osteosarcoma, there were 46 suicides of 17,155 patients, accounting for 35% of all suicides among patients with malignant bone tumors. The patients with osteosarcoma had the highest suicide risk among all patients with bone tumors (34.55/100,000 person-years; SMR = 3.72; 95% CI [2.79–4.97]). The patients with chordoma had a minimal number of suicides, and those had the highest risk of accidental death (145.74/100,000 person-years; SMR = 2.98; 95% CI [2.17–4.09]).

3.4. Types of surgery related to a higher risk of suicide and accidental death

A total of 85 suicides and 207 accidental deaths were identified among patients who underwent surgery for malignant bone tumors. Compared with patients who did not undergo surgery (SMR = 1.84; 95% CI [0.99-3.43]), the patients who underwent surgery (SMR = 2.02; 95% CI [1.63-2.49]) had a higher suicide risk. Among patients who underwent surgery, amputation had a significantly higher suicide risk than those who underwent limb salvage surgery (SMR = 3.99; 95% CI [2.52-6.34] and SMR = 1.53; 95% CI [1.12-2.07]) (Table 2). Patients who did not undergo surgery had a higher risk of accidental death than those who underwent surgery (SMR = 2.42; 95% CI [1.82-3.22] and SMR = 1.64; 95% CI [1.43–1.88]). Among patients who underwent surgery, patients who underwent amputation or limb salvage had a higher risk of accidental death compared with the general population (SMR = 1.61; 95% CI [1.07-2.42] and SMR = 1.67; 95% CI [1.41-1.98]).

3.5. Internal comparisons: risk factors linked to a higher risk of suicide and accidental death based on Cox regression model

Male sex was found to be strongly associated with suicide (HR = 3.48; 95% CI [2.16–5.62]; P < 0.001) and accidental death (HR = 1.99; 95% CI [1.53–2.58]; P < 0.001) among patients with primary malignant bone tumors (Table 3). The risk of suicide for whites was three times that of blacks (HR = 3.71; 95% CI [1.17–11.73]; P = 0.025). Patients with bone tumors of the extremities (HR = 1.66; 95% CI [1.03–2.69]; P = 0.038) or regional bone tumors (HR = 3.07; 95% CI [1.09–8.64]; P = 0.034) had higher suicide risk. Besides, the patients whose age at diagnosis was more than

60 years old were at higher risk of suicide (HR = 4.04; 95% CI [1.98–8.26]; P < 0.001) and accidental death (HR = 1.60; 95% CI [1.09–2.37]; P < 0.001) than other age subgroups. Compared with limb salvage, amputation significantly increased the risk of suicide (HR = 2.32; 95% CI [1.31–4.09]; P < 0.001), Fig. 4 but did not increase the risk of accidental death (HR = 1.11; 95% CI [0.71–1.74]; P = 0.65) Fig. 5, using the Cox proportional hazards model.

3.6. Risk of suicide and accidental deaths with time since diagnosis

Among patients with malignant bone tumors, the risk of suicide was the highest in the first year after diagnosis, decreased gradually from 1 year to 10 years, and increased after 10 years Table 4. The risk of accidental death was also the highest in the first year after diagnosis, but decreased gradually from 1 year to 5 years, and increased after 5 years Table 4.

4. Discussion

It has been recognised that cancer patients have a higher risk of suicide or accidental death than the general population [4,11]. We first reported that the risk of suicide among patients with malignant bone tumors was 2 times that of the general population, and the risk of accidental death was 1.7 times that of the general population. Bone tumors can cause psychological stress, physical disabilities, and social dysfunction [9,10], which increases the risk of suicide and accidental death [6].

Our study has several limitations. First, the SEER database contains detailed information regarding chemoradiotherapy. Earlier studies have shown that radiotherapy could induce cognitive dysfunction among patients with cancer of the head and neck [19,20], which might increase the risk of accidental death [11]. Furthermore, we do not know the regimens of radiotherapy from the SEER database, such as cycles, which renders it difficult to assess the direct association between radiotherapy and the risk of accidental death among patients with bone tumors of the skull and face. Second, data on psychiatric status, quality of life, and social support are also unavailable in the SEER database. Therefore, we could not evaluate the impact of these factors on the risk of suicide and accidental death. This study is the first large populationbased study on the risk of suicide and accidental death in patients with malignant bone tumors. Hence, the results of the study are reliable and applicable to the rest of the population (Table 4).

Using data from the SEER database, we found that surgery, especially amputation, significantly increased suicide risk among patients with malignant bone tumors. The principle treatment for bone tumors was surgery. Visible changes in the body, such as physical disability and deviating appearance, occurred in patients with bone tumors following surgical treatment [6,8]. These changes decreased the quality of life and caused a series of mental illnesses such as depression or anxiety [9,10]. Bone tumors in the pelvis and extremities may require extensive surgery [21], and higher suicide risk in patients with malignant bone tumors of the extremities and pelvis may be related to surgery. It was difficult for patients with bone tumors of the extremities to cover up the physical disabilities and appearance deviation caused by surgery. For these cancer survivors, exposing the deviating appearance to others was a challenge in social situations, which decreased their participation in social and recreational activities and increased the level of depression and demoralization [8]. Higher levels of depression and anxiety have been shown in cancer patients with amputation [14,15]. The bone tumors of the pelvis were associated with more complicated resections and higher recurrence rates [22], and worse prognosis had a negative effect on psychological healthy [22–24]. Brianna et al. reported that patients with bone and soft

Table 1

The risks of suicide and accident death among patients with primary malignant bone tumors diagnosed between 1 January 1973 and 31 December 2017.

No. of deathMontily reiSMR (9300)No. of eachMontily reiSMR (9300)Sex	Variable	No. of Patients	Person-years	Suicides [†]		Accident deaths [†]			
Sex				No. of deaths	Mortality rate [‡]	SMR (95%CI)	No. of deaths	Mortality rate [‡]	SMR (95%CI)
Female 22.039 18.281.96 21 11.52 2.88 (1.88-44.9) 82 44.99 2.64 (2.12-32.7) Male 28.778 21459.54 87 40.56 2.74 (2.2-3.3) 18.4 85.78 2.26 (1.95-2.61) Race 7.96 18.0 (0.85-57) 17 45.11 18.11 (1.15-2.92) White 41.682 32654.23 105 32.16 2.97 (2.45-36) 32.2 7.105 2.39 (2.10-2.72) Other 42.61 32559.71 0 0.00 0.00 17 52.21 2.75 (1.71-4.42) S1995-2006 17.2.81 51896.73 52 2.74 2.50 (1.86-3.61) 120 7.98 (3.62-5.3.64) 2007-2017 21.170 7.454.54 26 35.01 4.14 (2.82-6.08) 55 7.07 2.87 (2.20-3.74) Dispo-2006 17.281 51896.83 25 16.46 2.38 (1.61-3.53) 96 63.20 3.71 (1.41-2.23) Doma 13.269 82925.67 34 38.06 2.16 (1.36-3.44) <th< td=""><td>Sex</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	Sex								
Male 28,778 214509.54 87 40.56 2.74 (2.22-3.38) 184 85.78 2.26 (1.95-2.61) Black 4874 37689.46 3 7.96 1.80 (0.58-5.57) 17 45.11 1.81 (1.13-2.92) Other 4.261 32559.71 0 0.00 0.00 17 52.21 2.75 (1.71-4.42) Vertor diagonsi 1 1 1.13.259 38 (1.16-2.91) 53 55.73 1.95 (1.49-2.55) 1995-1905 7091 90959542 18 18.93 1.84 (1.16-2.91) 53 55.73 1.95 (1.49-2.55) 1996-2006 17.281 153892.67 35 22.74 2.59 (1.86-3.61) 120 77.98 3.05 (2.55-3.64) 2007-2017 21.170 74254.54 2.6 3.50 74.07 2.37 (1.30-4.45) Median 18,638 15906.83 2.5 16.46 2.38 (1.81-4.17) 75 63.20 3.17 (1.41-2.31) Unknow 2.369 364650 15 41.13 3.18 (2.41-3.41) <td>Female</td> <td>22,039</td> <td>182281.96</td> <td>21</td> <td>11.52</td> <td>2.88 (1.88-4.42)</td> <td>82</td> <td>44.99</td> <td>2.64 (2.12-3.27)</td>	Female	22,039	182281.96	21	11.52	2.88 (1.88-4.42)	82	44.99	2.64 (2.12-3.27)
Rack Job 10 Job 10 <thjob 10<="" th=""> <thjob 10<="" td="" tho<=""><td>Male</td><td>28,778</td><td>214509.54</td><td>87</td><td>40.56</td><td>2.74 (2.22-3.38)</td><td>184</td><td>85.78</td><td>2.26 (1.95-2.61)</td></thjob></thjob>	Male	28,778	214509.54	87	40.56	2.74 (2.22-3.38)	184	85.78	2.26 (1.95-2.61)
Black 4874 37689.46 3 7.96 1.80 (0.58-5.57) 1.7 45.11 1.81 (1.13-2.92) Othire 4261 32559.71 0 0.00 0.00 17 52.21 2.75 (1.71-4.21) Pear of diggonsi 1 1 1.13 (1.13-2.92) 3.00 (2.13-6.02) 3.8 51.67 1.42 (1.03-1.95) 1993-1984 5275 73548.88 2.9 3.9.3 3.07 (2.13-4.42) 3.8 51.67 1.42 (1.03-1.95) 1993-2006 17.281 153892.67 3.5 2.2.74 2.59 (1.86-361) 1.20 77.98 3.05 (2.55-3.64) 2007-2017 21.170 74254.54 2.6 2.5.10 4.14 (2.82-6.08) 55 74.07 2.38 (1.43-3.17) Bedian 18,638 151906.83 2.5 1.41.13 3.84 (2.04-5.61) 2.2 60.33 1.39 (0.92-2.12) Luknow 2.269 2.658 2.03 (1.57-2.63) 1.22 (2.09-0.15) 1.20 1.99 (0.92-1.22) 1.03 (1.91-3.71) 7.2 2.13 (2.10-3.71) Lu	Race								
White 41.682 326542.33 105 32.16 2.97 (2.43-3.60) 232 71.05 2.39 (2.10-2.72) Year of diagnosis	Black	4874	37689.46	3	7.96	1.80 (0.58-5.57)	17	45.11	1.81 (1.13-2.92)
Other 4261 32559.71 0 0.00 0.00 17 52.21 2.75 (1.71-4.42) 1973-1984 5275 73548.88 29 39.43 3.07 (2.13-4.2) 38 51.67 1.42 (1.03-1.95) 1985-1995 7091 95095.42 18 18.93 1.84 (1.62-91) 53 55.73 1.95 (1.49-2.55) 1996-2006 17.281 133892.67 35 2.2.74 2.59 (1.86-3.61) 120 77.38 3.05 (2.55-3.64) 2007-2017 21.170 74254.54 2.6 35.01 4.14 (2.82-6.08 55 74.07 2.87 (2.20-3.74) Income	White	41,682	326542.33	105	32.16	2.97 (2.45-3.60)	232	71.05	2.39 (2.10-2.72)
1973-198452773548.882939.433.07 (2.13-4.2)3851.671.42 (1.03-1.95)1985-1995709195095.421818.831.84 (1.6-2.91)5355.731.95 (1.40-2.55)2007-201721.17074254.542635.014.14 (2.82-6.08)5574.072.87 (2.20-3.74)10000119125.503428.542.98 (1.51-3.53)9663.203.71 (3.04-4.53)10000136.909329.2673438.082.67 (1.91-3.74)7381.751.77 (1.41-2.23)100000256036466.50154.1133.38 (2.04-5.61)2260.331.39 (0.92-2.12)1000000256036466.50154.133.38 (2.04-5.61)2260.331.39 (0.92-2.12)1000000000000000000000000000000000000	Other	4261	32559.71	0	0.00	0.00	17	52.21	2.75 (1.71-4.42)
1973-1984 275 73548.88 29 39.43 307 (21.4.42) 38 51.67 1.42 (1.03-1.95) 1985-1995 7091 95065.42 18 18.93 1.84 (1.16-2.91) 53 55.73 1.95 (1.40-2.55) 1906-2006 17.281 153892.67 35 2.274 2.59 (1.68-3.61) 120 77.98 3.05 (2.55-3.64) 2007-2017 2.1,170 74254.54 2.6 35.01 4.14 (2.82-60) 55 74.07 2.87 (2.20-3.74) Income	Year of diagnosis								
1985-1995 7091 9509542 18 18.93 1.84 (1.6-2.91) 53 55.73 1.95 (1.49-2.55) 1996-2006 17.281 153892.67 35 2.274 2.59 (1.86-3.61) 120 77.98 305 (2.55-3.64) 2007-2017 21.170 74254.54 26 35.01 4.14 (2.82-6.08) 55 74.07 2.87 (2.20-3.74) Income	1973-1984	5275	73548.88	29	39.43	3.07 (2.13-4.42)	38	51.67	1.42 (1.03-1.95)
1996-2006 17,281 15389,267 35 22,74 2.59 (1,86-3.61) 120 77,98 305 (2,55-3.64) 2007-2017 21,170 74254,54 26 35.01 4.14 (2,82-6.08) 55 74.07 2,87 (2,20-3.74) Income	1985-1995	7091	95095.42	18	18.93	1.84 (1.16-2.91)	53	55.73	1.95 (1.49-2.55)
2007-2017 21,170 74254.54 26 35.01 4.14 (282-6.08) 55 74.07 2.87 (220-3.74) Income	1996-2006	17,281	153892.67	35	22.74	2.59 (1.86-3.61)	120	77.98	3.05 (2.55-3.64)
Income Income Income High 18,538 151906.83 25 16.46 2.38 (161-3.53) 96 63.20 3.71 (304-4.53) Median 16,6450 119125.50 34 28.54 2.98 (2.13-4.17) 75 62.96 2.53 (2.01-3.17) Low 13,269 89292.67 34 38.08 2.67 (1.91-3.74) 73 81.75 1.77 (1.41-2.23) Unknown 2560 36466.50 15 41.13 338 (2.04-5.61) 22 60.33 1.39 (0.92-2.12) Education 8 96.85 2.03 (1.57-2.63) Median 11,627 10392.84 29 27.90 2.07 (1.44-2.98) 74 71.20 2.19 (1.74-2.74) Unknown 17.588 184074.57 37 2.641 8.34 (6.04-1.51) 92 65.68 5.83 (4.75-7.15) Stage 16.4142.67 47 32.53 3.35 (2.51-4.45) 94 65.07 2.30 (1.88-2.81) Distant	2007-2017	21,170	74254.54	26	35.01	4.14 (2.82-6.08)	55	74.07	2.87 (2.20-3.74)
High18,53815190.6.332516.462.38 (1.61 - 5.31)966.3.203.71 (3.04 - 4.53)Median16,450119125.503428.542.98 (2.13 - 4.17)7562.962.53 (2.01 - 3.17)Low13,2698920.673438.082.67 (1.91 - 3.74)738.1.751.77 (1.41 - 2.23)Unknown256036466.501541.133.32 (2.04 - 5.61)2260.331.39 (0.92 - 2.12)EducationTT <td>Income</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Income								
Median 16,450 119125.50 34 28,54 2.98 (2.13-4.17) 75 62.96 2.53 (2.01-3.17) Low 13,269 89292.67 34 38.08 2.67 (1.91-3.74) 73 81.75 1.77 (1.41-2.23) Unknown 2560 354665.0 15 41.13 3.38 (2.04-5.61) 22 60.33 1.39 (0.92-2.12) Education <t< td=""><td>High</td><td>18,538</td><td>151906.83</td><td>25</td><td>16.46</td><td>2.38 (1.61-3.53)</td><td>96</td><td>63.20</td><td>3.71 (3.04-4.53)</td></t<>	High	18,538	151906.83	25	16.46	2.38 (1.61-3.53)	96	63.20	3.71 (3.04-4.53)
low 13,269 8929,267 34 38,08 2,67 (1,91-3,74) 73 81,75 1,77 (1,41-2,23) Unknown 2560 36466.50 15 41,13 3.36 (2,04-5,61) 22 60.33 1,39 (0,92-2,12) High 10,241 59888.38 18 30.06 2.16 (1,36-3,44) 58 96.85 2.03 (1,57-2,63) Low 11,627 103928.04 29 27.90 2.07 (1,44-2,98) 74 71.20 2.19 (1,74-2,74) Unknown 17,558 144074.75 37 2.641 8.34 (6,04-11.51) 92 65.68 5.83 (4,75-7.15) Stage 2 2.730 2.07 (1,44-2,98) 74 71.20 2.19 (1,74-2,74) Unknown 16,628 31543.3 4 12.68 13.35 (2,51-4,45) 94 65.07 2.30 (1,88-2,81) Distart 86628 31543.33 4 12.68 1.47 (0,55-3,92) 18 57.06 2.21 (1,39-3,51) Unknown 6660 39323.53 5 2.987	Median	16,450	119125.50	34	28.54	2.98 (2.13-4.17)	75	62.96	2.53 (2.01-3.17)
Unknown 2560 36466.50 15 41.13 3.38 (2.04-5.61) 22 60.33 1.39 (0.92-2.12) Education	Low	13,269	89292.67	34	38.08	2.67 (1.91-3.74)	73	81.75	1.77 (1.41-2.23)
Education Instruction Instruction High 10,241 59888.38 18 30.06 2.16 (1.36-3.44) 58 96.85 2.03 (1.57-2.63) Low 11,561 92900.33 24 25.83 1.95 (1.31-2.91) 42 45.21 1.22 (0.90-1.65) Low 11,627 103928.04 29 27.90 2.07 (1.44-2.98) 74 71.20 2.19 (1.74-2.74) Unknown 17,588 140074.75 37 26.41 8.34 (6.04-11.51) 92 65.68 5.83 (4.75-7.15) Stage 1 124 68.33 2.40 (2.01-2.86) 124 68.33 2.40 (2.01-2.86) Iokanow 8660 3932.63 9 2.2.89 2.37 (1.23-4.55) 94 65.07 2.30 (1.88-2.81) Unknown 6660 3932.63 9 2.2.89 2.37 (1.23-4.55) 30 7.62.9 2.53 (1.7764) Upper limb 20,774 184135.63 55 2.98.7 3.46 (2.65-4.50) 101 5.4.85 2.51 (1.4-8.2)	Unknown	2560	36466.50	15	41.13	3.38 (2.04-5.61)	22	60.33	1.39 (0.92-2.12)
High10,24159888.381830.062.16 (1.36-3.44)5896.852.03 (1.57-2.63)Median11,36192900.332425.831.95 (1.31-2.91)4245.211.22 (0.90-1.65)Low11,627103928.042927.902.07 (1.44-2.98)7471.202.19 (1.74-2.74)Unknown17,588140074.753726.418.34 (6.04-11.51)9265.685.83 (4.75-7.15)Stage	Education					. ,			
Median 11,361 92900.33 24 25.83 1.95 (1.31-2.91) 42 45.21 1.22 (0.90-1.65) Low 11,627 103928.04 29 27.90 2.07 (1.44-2.98) 74 71.20 2.19 (1.74-2.74) Unknown 17,588 140074.75 37 26.41 8.34 (6.04-11.51) 92 65.68 S83 (4.75-7.15) Stage 66.07 2.30 (1.88-2.81) Distant 8628 3154.3.33 4 12.68 1.47 (0.55-3.92) 18 57.06 2.21 (1.39-3.51) Unknown 6660 3932.63 9 22.89 2.37 (1.23-4.55) 30 76.29 2.53 (1.77-3.61) Unknown 6660 3932.363 9 22.89 2.37 (1.65-4.50) 101 54.85 2.18 (1.80-2.65) Upper limb 6409 55450.29 16 28.85 2.95 (1.81-4.82) 26 46.89 1.67 (1.14-2.45) Skull and Face 6910 52090.17 13	High	10,241	59888.38	18	30.06	2.16 (1.36-3.44)	58	96.85	2.03 (1.57-2.63)
Low 11,627 103928.04 29 27.90 2.07 (1.44-2.98) 74 71.20 2.19 (1.74-2.74) Unknown 17,588 140074.75 37 26.41 8.34 (6.04-11.51) 92 65.68 5.83 (4.75-7.15) Stage Localized 18,189 181461.88 48 26.45 2.60 (1.96-3.45) 124 68.33 2.40 (2.01-2.86) Distant 8628 31543.33 4 12.68 1.47 (0.55-3.92) 18 57.06 2.21 (1.39-3.51) Unknown 6660 39323.63 9 22.89 2.37 (1.23-4.55) 30 76.29 2.53 (1.74-2.74) Stere Upper limb 6409 55450.29 16 28.85 2.95 (1.81-4.82) 26 46.89 1.67 (1.42-2.45) Vertebral column 3507 22272.33 15 32.90 2.74 (1.65-4.55) 39 85.55 2.54 (1.86-3.48) Skull and Face 6910 52090.17 13 24.96 2.34 (1.36-4.04) 58 11.33 3.57 (2.76-4.62) <td>Median</td> <td>11,361</td> <td>92900.33</td> <td>24</td> <td>25.83</td> <td>1.95 (1.31-2.91)</td> <td>42</td> <td>45.21</td> <td>1.22 (0.90-1.65)</td>	Median	11,361	92900.33	24	25.83	1.95 (1.31-2.91)	42	45.21	1.22 (0.90-1.65)
Unknown17,588140074.753726.418.34 (6.04–11.51)9265.685.83 (4.75–7.15)StageLocalized18,189181461.884826.452.60 (1.96–3.45)12468.332.40 (2.01–2.86)Regional17,340144462.674732.533.35 (2.51–4.45)9465.072.30 (1.88–2.81)Distant862831543.33412.681.47 (0.55–3.92)1857.062.21 (1.39–3.51)Unknown66039323.63922.892.37 (1.23–4.55)3076.292.53 (1.77–3.61)Site*Image: Construction of the state stat	Low	11,627	103928.04	29	27.90	2.07 (1.44-2.98)	74	71.20	2.19 (1.74–2.74)
Stage V <td>Unknown</td> <td>17,588</td> <td>140074.75</td> <td>37</td> <td>26.41</td> <td>8.34 (6.04-11.51)</td> <td>92</td> <td>65.68</td> <td>5.83 (4.75-7.15)</td>	Unknown	17,588	140074.75	37	26.41	8.34 (6.04-11.51)	92	65.68	5.83 (4.75-7.15)
Localized 18,189 181461.88 48 26.45 2.60 (1.96-3.45) 124 68.33 2.40 (2.01-2.86) Regional 17,340 144462.67 47 32.53 3.35 (2.51-4.45) 94 65.07 2.30 (1.88-2.81) Distant 8628 31543.33 4 12.68 1.47 (0.55-3.92) 18 57.06 2.21 (1.39-3.51) Unknown 6660 39323.63 9 2.289 2.37 (1.23-4.55) 30 76.29 2.53 (1.77-3.61) Ste ^o 4.6409 54450.29 16 2.8.85 2.95 (1.81-4.82) 26 46.89 1.67 (1.14-2.45) Pelvis 7930 45587.33 15 32.90 2.74 (1.65-4.55) 39 85.55 2.54 (1.86-3.48) Skull and Face 6910 52090.17 13 24.96 2.34 (1.36-4.04) 58 111.35 3.57 (2.76-4.62) Vertebral column 3507 22272.33 3 13.47 1.21 (0.39-3.76) 33 148.17 4.83 (3.43	Stage					. ,			
Regional 17,340 144462.67 47 32.53 3.35 (2.51-4.45) 94 65.07 2.30 (1.88-2.81) Distant 8628 31543.33 4 12.68 1.47 (0.55-3.92) 18 57.06 2.21 (1.39-3.51) Unknown 6660 39323.63 9 22.89 2.37 (1.23-4.55) 30 76.29 2.53 (1.77-3.61) Site* 94 65.07 2.30 (1.88-2.81) Lower limb 20,774 184135.63 55 29.87 3.46 (2.65-4.50) 101 54.85 2.18 (1.80-2.65) Upper limb 6409 55450.29 16 28.85 2.95 (1.81-4.82) 26 46.89 1.67 (1.14-2.45) Pelvis 7930 45587.33 15 32.90 2.74 (1.65-4.55) 39 85.55 2.54 (1.86-3.48) Skull and Face 6910 52090.17 13 24.96 2.34 (1.36-4.04) 58 111.35 3.57 (2.76-4.62) Thorax 3736 30705.58 6	Localized	18,189	181461.88	48	26.45	2.60 (1.96-3.45)	124	68.33	2.40 (2.01-2.86)
Distant 8628 31543.33 4 12.68 1.47 (0.55-3.92) 18 57.06 2.21 (1.39-3.51) Unknown 6660 39323.63 9 22.89 2.37 (1.23-4.55) 30 76.29 2.53 (1.77-3.61) Site®	Regional	17,340	144462.67	47	32.53	3.35 (2.51-4.45)	94	65.07	2.30 (1.88-2.81)
Unknown 6660 39323.63 9 22.89 2.37 (1.23-4.55) 30 76.29 2.53 (1.77-3.61) Site* Lower limb 20,774 184135.63 55 29.87 3.46 (2.65-4.50) 101 54.85 2.18 (1.80-2.65) Upper limb 6409 55450.29 16 28.85 2.95 (1.81-4.82) 26 46.89 1.67 (1.14-2.45) Pelvis 7930 45587.33 15 32.90 2.74 (1.65-4.55) 39 85.55 2.54 (1.86-3.48) Skull and Face 6910 52090.17 13 24.96 2.34 (1.36-4.04) 58 11.135 3.57 (2.76-462) Thorax 3736 30705.58 6 19.54 1.67 (0.75-3.72) 6 19.54 0.59 (0.26-1.31) Vertebral column 3507 2.272.33 3 13.47 1.21 (0.39-3.76) 33 148.17 4.83 (3.43-6.79) Others 1551 6550.17 0 0.00 0.00	Distant	8628	31543.33	4	12.68	1.47 (0.55-3.92)	18	57.06	2.21 (1.39-3.51)
Site ⁵ Lower limb 20,774 184135.63 55 29.87 3.46 (2.65-4.50) 101 54.85 2.18 (1.80-2.65) Upper limb 6409 55450.29 16 28.85 2.95 (1.81-4.82) 26 46.89 1.67 (1.14-2.45) Pelvis 7930 45587.33 15 32.90 2.74 (1.65-4.55) 39 85.55 2.54 (1.86-3.48) Skull and Face 6910 52090.17 13 24.96 2.34 (1.36-4.04) 58 111.35 3.57 (2.76-4.62) Thorax 3736 30705.58 6 19.54 1.67 (0.75-3.72) 6 19.54 0.59 (0.26-1.31) Vertebral column 3507 22272.33 3 13.47 1.21 (0.39-3.76) 33 148.17 4.83 (3.43-6.79) Others 1551 6550.17 0 0.00 0.00 3 45.80 1.40 (0.45-4.35) Type [*] 0 0 0.00 0.00 3 45.80 1.40 (0.45-4.35) Veryge sarcoma 17.15	Unknown	6660	39323.63	9	22.89	2.37 (1.23-4.55)	30	76.29	2.53 (1.77-3.61)
Lower limb20,774184135.635529.873.46 (2.65-4.50)10154.852.18 (1.80-2.65)Upper limb640955450.291628.852.95 (1.81-4.82)2646.891.67 (1.14-2.45)Pelvis793045587.331532.902.74 (1.65-4.55)3985.552.54 (1.86-3.48)Skull and Face691052090.171324.962.34 (1.36-4.04)58111.353.57 (2.76-4.62)Thorax373630705.58619.541.67 (0.75-3.72)619.540.59 (0.26-1.31)Vertebral column350722272.33313.471.21 (0.39-3.76)33148.174.83 (3.43-6.79)Others15516550.1700.000.00345.801.40 (0.45-4.35)Type*Osteosarcoma17,155133144.294634.554.61 (3.45-6.15)7657.082.53 (2.02-3.17)Chordrosarcoma13,895126683.833930.792.41 (1.76-3.29)6954.471.56 (1.23-1.98)Ewing sarcoma729453812.631018.583.04 (1.63-5.65)254.64.642.49 (1.68-3.68)Chordoma398226073.29311.510.86 (0.28-2.68)38145.743.96 (2.88-5.45)Others849157077.461017.521.64 (0.88-3.06)58101.623.09 (2.39-3.99)SurgeryYes38,116329260.588525.82 <td>Site§</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>· · · ·</td>	Site§								· · · ·
Upper limb640955450.291628.852.95 (1.81-4.82)2646.891.67 (1.14-2.45)Pelvis793045587.331532.902.74 (1.65-4.55)3985.552.54 (1.86-3.48)Skull and Face691052090.171324.962.34 (1.36-4.04)58111.353.57 (2.76-4.62)Thorax373630705.58619.541.67 (0.75-3.72)619.540.59 (0.26-1.31)Vertebral column350722272.33313.471.21 (0.39-3.76)33148.174.83 (3.43-6.79)Others15516550.1700.000.00345.801.40 (0.45-4.35)Type*Osteosarcoma17,155133144.294634.554.61 (3.45-6.15)7657.082.53 (2.02-3.17)Chondrosarcoma13,895126683.833930.792.41 (1.76-3.29)6954.471.56 (1.23-1.98)Ewing sarcoma729453812.631018.583.04 (1.63-5.65)2546.462.49 (1.68-3.68)Others849157077.461017.521.64 (0.88-3.06)5810.1623.09 (2.39-3.99)SurgeryYes38,116329260.588525.822.57 (2.08-3.18)20762.868142.23 (1.94-2.55)None10,10846175.001021.662.61 (1.41-4.86)47101.793.71 (2.79-4.90)Munkown259321355.421360.876	Lower limb	20,774	184135.63	55	29.87	3.46 (2.65-4.50)	101	54.85	2.18 (1.80-2.65)
Peivis793045587.331532.902.74 (1.65-4.55)3985.552.54 (1.86-3.48)Skull and Face691052090.171324.962.34 (1.36-4.04)58111.353.57 (2.76-4.62)Thorax373630705.58619.541.67 (0.75-3.72)619.540.59 (0.26-1.31)Vertebral column350722272.33313.471.21 (0.39-3.76)33148.174.83 (3.43-6.79)Others1551650.1700.000.00345.801.40 (0.45-4.35)Type*Osteosarcoma17,155133144.294634.554.61 (3.45-6.15)7657.082.53 (2.02-3.17)Chondrosarcoma13,895126683.833930.792.41 (1.76-3.29)6954.471.56 (1.23-1.98)Ewing sarcoma729453812.631018.583.04 (1.63-5.65)2546.462.49 (1.68-3.68)Chordoma398226073.29311.510.86 (0.28-2.68)38145.743.96 (2.88-5.45)Others849157077.461017.521.64 (0.88-3.06)58101.623.09 (2.39-3.99)SurgeryYes38,116329260.588525.822.57 (2.08-3.18)20762.868142.23 (1.94-2.55)None10,10846175.001021.662.61 (1.41-4.86)47101.793.71 (2.79-4.94)Unknown259321355.421360.876.11	Upper limb	6409	55450.29	16	28.85	2.95 (1.81-4.82)	26	46.89	1.67 (1.14-2.45)
Skull and Face 6910 52090.17 13 24.96 2.34 (1.36-4.04) 58 111.35 3.57 (2.76-4.62) Thorax 3736 30705.58 6 19.54 1.67 (0.75-3.72) 6 19.54 0.59 (0.26-1.31) Vertebral column 3507 22272.33 3 13.47 1.21 (0.39-3.76) 33 148.17 4.83 (3.43-6.79) Others 1551 6550.17 0 0.00 0.00 3 45.80 1.40 (0.45-4.35) Type* 0 0.00 0.00 3 45.80 1.40 (0.45-4.35) Chordrosarcoma 17,155 133144.29 46 34.55 4.61 (3.45-6.15) 76 57.08 2.53 (2.02-3.17) Chordrosarcoma 13,895 126683.83 39 30.79 2.41 (1.76-3.29) 69 54.47 1.56 (1.23-1.98) Ewing sarcoma 72.94 53812.63 10 18.58 3.04 (1.63-5.65) 25 46.46 2.49 (1.68-3.68) Chordoma 3982 26073.29 <td>Pelvis</td> <td>7930</td> <td>45587.33</td> <td>15</td> <td>32.90</td> <td>2.74 (1.65-4.55)</td> <td>39</td> <td>85.55</td> <td>2.54 (1.86-3.48)</td>	Pelvis	7930	45587.33	15	32.90	2.74 (1.65-4.55)	39	85.55	2.54 (1.86-3.48)
Thorax373630705.58619.541.67 (0.75-3.72)619.540.59 (0.26-1.31)Vertebral column350722272.33313.471.21 (0.39-3.76)33148.174.83 (3.43-6.79)Others15516550.1700.000.00345.801.40 (0.45-4.35)Type*Osteosarcoma17,155133144.294634.554.61 (3.45-6.15)7657.082.53 (2.02-3.17)Chondrosarcoma13,895126683.833930.792.41 (1.76-3.29)6954.471.56 (1.23-1.98)Ewing sarcoma729453812.631018.583.04 (1.63-5.65)2546.462.49 (1.68-3.68)Chordoma398226073.29311.510.86 (0.28-2.68)38145.743.96 (2.88-5.45)Others849157077.461017.521.64 (0.88-3.06)58101.623.09 (2.39-3.99)SurgeryYes38,116329260.588525.822.57 (2.08-3.18)20762.868142.23 (1.94-2.55)None10,10846175.501021.662.61 (1.41-4.86)47101.793.71 (2.79-4.94)Unknown259321355.421360.876.11 (3.55-10.53)1256.191.70 (0.97-3.00)All50.817396791.5010827.222.77 (2.29-3.34)26667.042.36 (2.09-2.66)	Skull and Face	6910	52090.17	13	24.96	2.34 (1.36-4.04)	58	111.35	3.57 (2.76-4.62)
Vertebral column 3507 22272.33 3 13.47 1.21 (0.39-3.76) 33 148.17 4.83 (3.43-6.79) Others 1551 6550.17 0 0.00 0.00 3 45.80 1.40 (0.45-4.35) Type ⁶ 7 7 7.155 133144.29 46 34.55 4.61 (3.45-6.15) 76 57.08 2.53 (2.02-3.17) Chondrosarcoma 13,895 126683.83 39 30.79 2.41 (1.76-3.29) 69 54.47 1.56 (1.23-1.98) Ewing sarcoma 7294 53812.63 10 18.58 3.04 (1.63-5.65) 25 46.46 2.49 (1.68-3.68) Chordoma 3982 26073.29 3 11.51 0.86 (0.28-2.68) 38 145.74 3.96 (2.88-5.45) Others 8491 57077.46 10 17.52 1.64 (0.88-3.06) 58 101.62 3.09 (2.39-3.99) Surgery Yes 38,116 329260.58 85 25.82 2.57 (2.08-3.18) 207 62.86814 2.23 (1.94-2.55)	Thorax	3736	30705.58	6	19.54	1.67 (0.75-3.72)	6	19.54	0.59 (0.26-1.31)
Others 1551 6550.17 0 0.00 0.00 3 45.80 1.40 (0.45-4.35) Type ¹ 0 0.00 0.00 3 45.80 1.40 (0.45-4.35) Osteosarcoma 17,155 133144.29 46 34.55 4.61 (3.45-6.15) 76 57.08 2.53 (2.02-3.17) Chondrosarcoma 13,895 126683.83 39 30.79 2.41 (1.76-3.29) 69 54.47 1.56 (1.23-1.98) Ewing sarcoma 7294 53812.63 10 18.58 3.04 (1.63-5.65) 25 46.46 2.49 (1.68-3.68) Chordoma 3982 26073.29 3 11.51 0.86 (0.28-2.68) 38 145.74 3.96 (2.88-5.45) Others 8491 57077.46 10 17.52 1.64 (0.88-3.06) 58 101.62 3.09 (2.39-3.99) Surgery Yes 38,116 329260.58 85 25.82 2.57 (2.08-3.18) 207 62.86814 2.23 (1.94-2.55) None 10,108 46175.50 10	Vertebral column	3507	22272.33	3	13.47	1.21 (0.39-3.76)	33	148.17	4.83 (3.43-6.79)
Type*Osteosarcoma17,155133144.294634.554.61 (3.45-6.15)7657.082.53 (2.02-3.17)Chondrosarcoma13,895126683.833930.792.41 (1.76-3.29)6954.471.56 (1.23-1.98)Ewing sarcoma729453812.631018.583.04 (1.63-5.65)2546.462.49 (1.68-3.68)Chordoma398226073.29311.510.86 (0.28-2.68)38145.743.96 (2.88-5.45)Others849157077.461017.521.64 (0.88-3.06)58101.623.09 (2.39-3.99)SurgeryYes38,116329260.588525.822.57 (2.08-3.18)20762.868142.23 (1.94-2.55)None10,10846175.01021.662.61 (1.41-4.86)47101.793.71 (2.79-4.94)Unknown259321355.421360.876.11 (3.55-10.53)1256.191.70 (0.97-3.00)All50.817396791.5010827.222.77 (2.29-3.34)26667.042.36 (2.09-2.66)	Others	1551	6550.17	0	0.00	0.00	3	45.80	1.40 (0.45-4.35)
Osteosarcoma 17,155 133144.29 46 34.55 4.61 (3.45-6.15) 76 57.08 2.53 (2.02-3.17) Chondrosarcoma 13,895 126683.83 39 30.79 2.41 (1.76-3.29) 69 54.47 1.56 (1.23-1.98) Ewing sarcoma 7294 53812.63 10 18.58 3.04 (1.63-5.65) 25 46.46 2.49 (1.68-3.68) Chordoma 3982 26073.29 3 11.51 0.86 (0.28-2.68) 38 145.74 3.96 (2.88-5.45) Others 8491 57077.46 10 17.52 1.64 (0.88-3.06) 58 101.62 3.09 (2.39-3.99) Surgery Yes 38,116 329260.58 85 25.82 2.57 (2.08-3.18) 207 62.86814 2.23 (1.94-2.55) None 10,108 46175.50 10 21.66 2.61 (1.41-4.86) 47 101.79 3.71 (2.79-4.94) Unknown 2593 21355.42 13 60.87 6.11 (3.55-10.53) 12 56.19 1.70 (0.97-3.00) A	Type [¶]								
Chondrosarcoma13,895126683.833930.792.41 (1.76-3.29)6954.471.56 (1.23-1.98)Ewing sarcoma729453812.631018.583.04 (1.63-5.65)2546.462.49 (1.68-3.68)Chordoma398226073.29311.510.86 (0.28-2.68)38145.743.96 (2.88-5.45)Others849157077.461017.521.64 (0.88-3.06)58101.623.09 (2.39-3.99)SurgeryYes38,116329260.588525.822.57 (2.08-3.18)20762.868142.23 (1.94-2.55)None10,10846175.501021.662.61 (1.41-4.86)47101.793.71 (2.79-4.94)Unknown259321355.421360.876.11 (3.55-10.53)1256.191.70 (0.97-3.00)All50.817396791.5010827.222.77 (2.29-3.34)26667.042.36 (2.09-2.66)	Osteosarcoma	17,155	133144.29	46	34.55	4.61 (3.45-6.15)	76	57.08	2.53 (2.02-3.17)
Ewing sarcoma 7294 53812.63 10 18.58 3.04 (1.63-5.65) 25 46.46 2.49 (1.68-3.68) Chordoma 3982 26073.29 3 11.51 0.86 (0.28-2.68) 38 145.74 3.96 (2.88-5.45) Others 8491 57077.46 10 17.52 1.64 (0.88-3.06) 58 101.62 3.09 (2.39-3.99) Surgery Y Yes 38,116 329260.58 85 25.82 2.57 (2.08-3.18) 207 62.86814 2.23 (1.94-2.55) None 10,108 46175.50 10 21.66 2.61 (1.41-4.86) 47 101.79 3.71 (2.79-4.94) Unknown 2593 21355.42 13 60.87 6.11 (3.55-10.53) 12 56.19 1.70 (0.97-3.00) All 50.817 396791.50 108 27.22 2.77 (2.29-3.34) 266 67.04 2.36 (2.09-2.66)	Chondrosarcoma	13,895	126683.83	39	30.79	2.41 (1.76-3.29)	69	54.47	1.56 (1.23-1.98)
Chordoma 3982 26073.29 3 11.51 0.86 (0.28-2.68) 38 145.74 3.96 (2.88-5.45) Others 8491 57077.46 10 17.52 1.64 (0.88-3.06) 58 101.62 3.09 (2.39-3.99) Surgery Yes 38,116 329260.58 85 25.82 2.57 (2.08-3.18) 207 62.86814 2.23 (1.94-2.55) None 10,108 46175.50 10 21.66 2.61 (1.41-4.86) 47 101.79 3.71 (2.79-4.94) Unknown 2593 21355.42 13 60.87 6.11 (3.55-10.53) 12 56.19 1.70 (0.97-3.00) All 50.817 396791.50 108 27.22 2.77 (2.29-3.34) 266 67.04 2.36 (2.09-2.66)	Ewing sarcoma	7294	53812.63	10	18.58	3.04 (1.63-5.65)	25	46.46	2.49 (1.68-3.68)
Others 8491 57077.46 10 17.52 1.64 (0.88-3.06) 58 101.62 3.09 (2.39-3.99) Surgery Yes 38,116 329260.58 85 25.82 2.57 (2.08-3.18) 207 62.86814 2.23 (1.94-2.55) None 10,108 46175.50 10 21.66 2.61 (1.41-4.86) 47 101.79 3.71 (2.79-4.94) Unknown 2593 21355.42 13 60.87 6.11 (3.55-10.53) 12 56.19 1.70 (0.97-3.00) All 50.817 396791.50 108 27.22 2.77 (2.29-3.34) 266 67.04 2.36 (2.09-2.66)	Chordoma	3982	26073.29	3	11.51	0.86 (0.28-2.68)	38	145.74	3.96 (2.88-5.45)
Surgery Yes 38,116 329260.58 85 25.82 2.57 (2.08-3.18) 207 62.86814 2.23 (1.94-2.55) None 10,108 46175.50 10 21.66 2.61 (1.41-4.86) 47 101.79 3.71 (2.79-4.94) Unknown 2593 21355.42 13 60.87 6.11 (3.55-10.53) 12 56.19 1.70 (0.97-3.00) All 50.817 396791.50 108 27.22 2.77 (2.29-3.34) 266 67.04 2.36 (2.09-2.66)	Others	8491	57077.46	10	17.52	1.64 (0.88-3.06)	58	101.62	3.09 (2.39–3.99)
Yes 38,116 329260.58 85 25.82 2.57 (2.08-3.18) 207 62.86814 2.23 (1.94-2.55) None 10,108 46175.50 10 21.66 2.61 (1.41-4.86) 47 101.79 3.71 (2.79-4.94) Unknown 2593 21355.42 13 60.87 6.11 (3.55-10.53) 12 56.19 1.70 (0.97-3.00) All 50.817 396791.50 108 27.22 2.77 (2.29-3.34) 266 67.04 2.36 (2.09-2.66)	Surgery								
None 10,108 46175.50 10 21.66 2.61 (1.41-4.86) 47 101.79 3.71 (2.79-4.94) Unknown 2593 21355.42 13 60.87 6.11 (3.55-10.53) 12 56.19 1.70 (0.97-3.00) All 50.817 396791.50 108 27.22 2.77 (2.29-3.34) 266 67.04 2.36 (2.09-2.66)	Yes	38,116	329260.58	85	25.82	2.57 (2.08-3.18)	207	62.86814	2.23 (1.94-2.55)
Unknown 2593 21355.42 13 60.87 6.11 (3.55-10.53) 12 56.19 1.70 (0.97-3.00) All 50.817 396791.50 108 27.22 2.77 (2.29-3.34) 266 67.04 2.36 (2.09-2.66)	None	10,108	46175.50	10	21.66	2.61 (1.41-4.86)	47	101.79	3.71 (2.79-4.94)
All 50.817 396791.50 108 27.22 2.77 (2.29-3.34) 266 67.04 2.36 (2.09-2.66)	Unknown	2593	21355.42	13	60.87	6.11 (3.55-10.53)	12	56.19	1.70 (0.97-3.00)
	All	50,817	396791.50	108	27.22	2.77 (2.29-3.34)	266	67.04	2.36 (2.09-2.66)

Abbreviations: SMR, standardized mortality ratio; CI, confidence intervals.

In this study, we included all patients with primary malignant bone tumors reported to the eighteen SEER registries (Alaska Native Tumor registry, Connecticut, Detroit, Atlanta, Greater Georgia, Rural Georgia, San Francisco–Oakland, San Jose–Monterey, Greater California, Kentucky, Los Angeles, Louisiana, Hawaii, Iowa, New Mexico, New Jersey, Seattle–Puget Sound, and Utah) diagnosed between January 1, 1973, and December 31, 2017. The data contributed by Idaho, Massachusetts and New York from January 1, 2000, and December 31, 2017 were also available.

¹ Suicide: International Classification of Diseases, Eighth Revision codes 950–959; International Classification of Diseases, Ninth Revision codes 950–959; and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes U03, X60-X84 and Y87.0. Accident death: International Classification of Diseases, Eighth Revision codes 800–949; International Classification of Diseases, Righth Revision codes 800–949; International Classification of Diseases, Ninth Revision codes 800–949; International Classification of Diseases, Righth Revision codes 800–949; International Classification of Diseases, Ninth Revision codes 800–949; and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision 485–986.

[‡] Per 100,000 person-years.

§ Specific primary site code (the International Statistical Classification of Diseases and Related Health Problems, the tenth revision [ICD-10 codes]): skull and face: C41.0, C41.1; thorax: C41.3; vertebral column: C41.2; pelvis: C41.4; upper limb: C40.0, C40.1; lower limb: C40.2, C40.3; others: C40.8, C40.9, C41.8, C41.9.

¹ The histological codes (International Classification of Diseases for Oncology, 3rd Edition [ICD-O-3]): Osteosarcoma: 9180/3–9200/3; Chondrosarcoma: 9220/3–9243/3; Ewing sarcoma: 9260/3; Chordoma: 9370/3–9372/3; Others: 8000/3–9150/3, 9250/3–9251/3, 9261/3–9365/3 and 9380/3–9580/3.

tissue cancer of the pelvis had a higher incidence of suicide [24], which was consistent with our study.

Osteosarcoma is the most common primary malignant bone tumour, and its treatment includes systemic multiagent chemotherapy and complete surgical resection [25]. In our study, the higher suicide risk in patients with osteosarcoma may be associated with surgery and location of osteosarcoma, which is usually found at the end of long bones and around the knees. Limb salvage surgery for osteosarcoma continued to improve with the development of chemotherapy and imaging, which was beneficial to improve the prognosis and might reduce the risk of suicide for patients with osteosarcoma.

The patients with bone tumors of the vertebral column or with chordoma had the highest risk of accidental death among all



Fig. 5. Kaplan-Meier survival curve for accident death among patients with malignant bone tumors. The result of log-rank indicated that there was no difference of risk of suicide between patients who underwent amputation and those who underwent limb salvage.

patients with malignant bone tumors. The higher risk of accidental death among patients with malignant bone tumors may be due to psychological stress, physical disabilities, and poor quality of life [6,9–11]. In addition, the tumors themselves and complications played an important role. Patients with spinal tumors usually present with spinal pain, limb weakness, and radiculopathy [26]. The clinical presentations of patients with chordoma mainly depended on the sites of chordoma, which can arise anywhere along the central neural axis from the skull base to the sacrum. Patients with chordomas of the skull base most often presented with headache, diplopia, and visual loss, and patients with spinal chordomas usually present with local deep pain, weakness, and numbness [27,28]. The symptoms could interfere with the normal work and life of cancer patients [29,30], might reduce the ability of patients to respond to emergency and increase the risk of death from unintentional injury. The reasons for the association of malignant bone tumors with a higher risk of accidental death warrant further investigation.

Meanwhile, the risk of accidental death in patients with malignant bone tumors of the skull and face was approximately three times that of the general population, and possible hypotheses to explain this association included cognitive impairment and epilepsy. Cancerrelated and treatment-induced cognitive dysfunction and epilepsy were common complications among patients with tumors of head and neck, also associated with pre-existing comorbidities [19,20,31]. Surgery could improve the complications, thus reducing the risk of accidental death among patients with bone tumors.

Although suicide was the second leading cause of death among the general population aged between 15 and 29 worldwide [3], it was reported that the suicide rate of adolescents and young cancer patients whose age at diagnosis was between 15 and 39 was marginally lower than that of all-age cancer patients [32], which was consistent with the results of our study. We first found that patients with bone tumors whose age at diagnosis was less than

15 had the highest SMR of suicide among all-age cancer patients, and the patients whose age at diagnosis was more than 60 years had a higher suicide risk than other age subgroups. The children and old patients with bone tumors were more likely to make unwise decisions because they could not get enough information about the tumour and psychological support from the Internet [33–35]. Suicides were preventable, and there were more than 20 attempts per suicide [3]. The Distress Assessment and Response Tool has been used to identify suicidal ideation in patients with cancer [36], and item 9 of the Patient Health Questionnaire depression module (PHQ9) was also a strong predictor of suicide attempts and suicide deaths in patients [37]. It was necessary to select patients whose age at diagnosis was less than 14 or more than 60 out when considering the suicide risk of patients with malignant bone tumors. Moreover, we should enhance these special patients' understanding of tumors and confidence to defeat diseases.

Our study demonstrated that patients with advanced bone tumors had the same risk of suicide and accidental death as the general population, which was at variance with prior works [4,11]. Possible hypotheses to explain this was that patients with advanced tumors had a worse prognosis, most of them died from bone tumour shortly after diagnosis, and shorter survival time obscured the risk of suicide or accidental death [38]. White patients with malignant bone tumors had a significantly higher suicide risk than black patients, which could be attributable to economic status, educational level, and culture factors [39,40].

We also found that the risk of suicide and accidental death was highest within the first year after initial diagnosis among patients with malignant bone tumors. The change in social status from being a healthy individual to being a cancer patient, even a disabled person, created a new identity [8]. Survivors with bone tumors needed enough time to accept these identity changes [8], which resulted in the highest risk of suicide and accidental death shortly after diagnosis [6,9,10]. This finding also underlines the concept that to better guide bone cancer survivors during followup, healthcare providers should have a comprehensive understanding of what this modification of identity means to survivors with malignant bone tumors [8].

The outcomes of this study indicated that patients with primary malignant bone tumors had a higher risk of suicide and accidental death than the general population, which was related to psychological stress and social dysfunction. It is worth noting that amputation due to bone tumors increased the risk of suicide but did not increase the risk of accidental death. Therefore, when selecting a surgical method for patients with malignant bone tumors, orthopaedic surgeons should not only consider the effect of surgery but also consider the acceptability of patients for postoperative physical changes such as deviating appearance. The suicides are preventable, but preventive measures for accidental deaths need further research. In order to reduce the risk of suicide and accidental death among patients with malignant bone tumors, clinicians should pay more attention to the psychological status, physical function, and cognitive level of these survivors.

Table 2

The risks of suicide and accident death among patients who underwent different surgery for malignant bone tumors.

Surgery	No. of Patients	Suicides			Accident deaths		
		No. of deaths	Mortality rate [†]	SMR (95%CI)	No. of deaths	Mortality rate †	SMR (95%CI)
Amputation Limb Salvage Surgery, NOS	5324 27,062 5730	18 41 26	50.05 19.58 30.99	5.47 (3.45–8.68) 2.18 (1.60–2.96) 2.37 (1.61–3.48)	23 134 50	63.95 64.00 59.59	2.40 (1.60–3.61) 2.53 (2.14–3.00) 1.64 (1.25–2.17)

Abbreviations: SMR, standardized mortality ratio; CI, confidence intervals.

[†] Per 100,000 person-years.

Table 3

Cox regression analyses of suicide and accidental death among patients with malignant bone tumors.

Variable	Suicides			Accident deaths			
	Hazard ratio	95% CI	P-value	Hazard ratio	95% CI	P-value	
Age at diagnosis							
0-14	_	_	Ref	_	-	Ref	
15-29	1.79	(0.92, 3.49)	0.086	0.58	(0.40, 0.86)	0.006	
30-44	1 90	(0.91, 4.00)	0.089	1.03	(0.70, 1.51)	0.873	
45-59	2.50	(121, 517)	0.014	0.93	(0.62, 1.39)	0 718	
60+	3.96	(1.24, 810)	0.000	161	(1.09, 2.38)	0.016	
Sex	0.00	(10 1, 0110)	0.000	1101	(1100, 2100)	01010	
Female	_	_	Ref	_	_	Ref	
Male	3 4 9	(2.16, 5.64)	0.000	1 99	(153, 259)	0.000	
Race	0110	(2110, 010 1)	0.000	100	(1100, 2100)	0.000	
Black	_	_	Ref	_	_	Ref	
White	4.08	(1.28, 12.94)	0.017	1 42	(0.86, 2.34)	0.168	
Other	0.00	NA	0.017	1.42	(0.50, 2.54)	0.100	
Vear of diagnosis	0.00	10/1	0.540	1.00	(0.54, 2.05)	0.005	
1973_1984	_	_	Ref	_	_	Ref	
1985_1995	0.77	(0.36, 1.66)	0.503	1 23	(0.71, 2.12)	0.456	
1985-1995	1.26	(0.50, 1.00)	0.505	2.25	(1.20, 4.08)	0.450	
2007 2017	1.20	(0.51, 5.10)	0.246	1.01	(1.20, 4.03)	0.011	
2007-2017	1.55	(0.01, 4.14)	0.540	1.51	(0.98, 3.74)	0.058	
lligh			Def			Dof	
Modian	- 1 57	-	0.097	-	- (0.72, 1.24)	0.020	
Low	2.60	(0.54, 2.04)	0.007	1.20	(0.75, 1.54)	0.930	
LOW	2.00	(1.42, 4.70)	0.002	1.20	(0.61, 1.77)	0.570	
	2.15	(0.91, 4.97)	0.081	1.17	(0.65, 2.10)	0.595	
Education			Def			Def	
High	-	-	Rei 0.580	-	-	Kel	
Median	1.21	(0.62, 2.37)	0.580	0.56	(0.36, 0.87)	0.011	
LOW	1.20	(0.76, 3.22)	0.230	0.93	(0.59, 1.45)	0.736	
	1.52	(0.64, 2.75)	0.452	0.79	(0.51, 1.25)	0.299	
Location			Def			Def	
AXIdi	-	-	Rel 0.047	-	-	Kel	
Extremities	1.03	(1.01, 2.64)	0.047	0.77	(0.57, 1.03)	0.082	
others Stars	1.23	(0.62, 2.44)	0.551	1.40	(1.00, 1.97)	0.052	
Stage			Def			Def	
	-	-	Rel 0.077	-	-	Kel 0.102	
Localized	2.55	(0.90, 7.22)	0.077	1.53	(0.92, 2.55)	0.103	
Regional	3.10	(1.10, 8.73)	0.032	1.33	(0.79, 2.22)	0.281	
Unknown	1.84	(0.56, 6.05)	0.317	1.32	(0.73, 2.39)	0.365	
Surgery							
Limb Salvage	-	-	Ket	-	-	Ret	
Amputation	2.27	(1.28, 4.01)	0.005	1.11	(0.71, 1.75)	0.638	
None	1.34	(0.66, 2.72)	0.424	1.62	(1.14, 2.31)	0.007	
Surgery, NOS	1.65	(0.74, 3.66)	0.221	1.34	(0.82, 2.18)	0.241	
Unknown	4.20	(1.71, 10.30)	0.002	1.41	(0.70, 2.86)	0.335	

[†] Axial included "Thorax", "Vertebral column" and "Pelvis"; Extremities included "Lower limb" and "Upper limb"; Others included "Others" and "Skull and Face".

Table 4

The risk of suicide and accident death by years since diagnosis.

Time since diagnosis	Suicides		Accident deaths	Accident deaths		
	No. of deaths	SMR (95%CI)	No. of deaths	SMR (95%CI)		
0 to 1y	18	4.26 (2.68-6.76)	41	3.04 (2.24-4.13)		
1y to 5y	39	2.76 (2.02-3.78)	75	1.80 (1.43-2.25)		
5y to 10y	15	0.93 (0.56-1.54)	61	1.34 (1.04-1.72)		
greater than10y	36	2.71 (1.98–3.75)	89	2.43 (1.98-3.00)		

Abbreviations: SMR, standardized mortality ratio; CI, confidence intervals.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

None.

Author contributions

K.Y., B.W and F.L. designed research. K.Y., B.W., and Y.C. calculated data. K.Y., H.K., K.S., Y.D., and P.P. analyzed result. K.Y., B.W., Y.C., H.K., K.S., Y.D., P.P., and F.L. wrote this paper. All authors revised the final version.

Studies in humans and animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability statement

Data analyzed in this study were from the Surveillance, Epidemiology and End Results database, which was publicly available datasets.

Conflict of Interest

Each author certifies that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/ licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article.

References

- [1] A. Tichelli, M. Labopin, A. Rovo, M. Badoglio, M. Arat, M.T. van Lint, A. Lawitschka, C.P. Schwarze, J. Passweg, G. Socie, Increase of suicide and accidental death after hematopoietic stem cell transplantation: a cohort study on behalf of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation (EBMT), Cancer 119 (11) (2013) 2012–2021.
- [2] M. Heron, Deaths: Leading Causes for 2016, National Vital Statistics Reports (2018).
- [3] Our World in Data: Cancer, (2 November 2019).
- [4] S. Misono, N.S. Weiss, J.R. Fann, M. Redman, B. Yueh, Incidence of suicide in persons with cancer, J. Clin. Oncol. 26 (29) (2008) 4731–4738.
- [5] A. Robson, F. Scrutton, L. Wilkinson, F. MacLeod, The risk of suicide in cancer patients: a review of the literature, Psychooncology 19 (12) (2010) 1250–1258.
- [6] H. Bergen, K. Hawton, N. Kapur, J. Cooper, S. Steeg, J. Ness, K. Waters, Shared characteristics of suicides and other unnatural deaths following non-fatal selfharm? A multicentre study of risk factors, Psychol. Med. 42 (4) (2012) 727– 741.
- [7] L. Fauske, O.S. Bruland, E.K. Grov, H. Bondevik, Cured of primary bone cancer, but at what cost: a qualitative study of functional impairment and lost opportunities, Sarcoma 2015 (2015) 484196.
- [8] L. Fauske, G. Lorem, E.K. Grov, H. Bondevik, Changes in the body image of bone sarcoma survivors following surgical treatment-a qualitative study, J. Surg. Oncol. 113 (2) (2016) 229–234.
- [9] T. Paredes, M.C. Canavarro, M.R. Simões, Anxiety and depression in sarcoma patients: emotional adjustment and its determinants in the different phases of disease, Eur. J. Oncol. Nurs. 15 (1) (2011) 73–79.
- [10] N. Rumsey, D. Harcourt, Body image and disfigurement: issues and interventions, Body Image 1 (1) (2004) 83–97.
- [11] K. Yang, Y. Zheng, J. Peng, J. Chen, H. Feng, K. Yu, Y. Chen, W. Luo, P. Yang, Y. Yang, B. Wu, Incidence of death from unintentional injury among patients with cancer in the United States, JAMA Netw Open 3 (2) (2020) e1921647, https://doi.org/10.1001/jamanetworkopen.2019.21647.
- [12] M.C. Balcı Şengül, V. Kaya, C.A. Şen, K. Kaya, Association between suicidal ideation and behavior, and depression, anxiety, and perceived social support in cancer patients, Med. Sci. Monit. 20 (2014) 329–336.
- [13] C.-K. Fang, M.-C. Chang, P.-J. Chen, C.-C. Lin, G.-S. Chen, J. Lin, R.-K. Hsieh, Y.-F. Chang, H.-W. Chen, C.-L. Wu, K.-C. Lin, Y.-J. Chiu, Y.-C. Li, A correlational study of suicidal ideation with psychological distress, depression, and demoralization in patients with cancer, Support. Care Cancer 22 (12) (2014) 3165–3174.
- [14] A. Cansever, O. Uzun, C. Yildiz, A. Ates, A.S. Atesalp, Depression in men with traumatic lower part amputation: a comparison to men with surgical lower part amputation, Mil. Med. 168 (2) (2003) 106–109.
- [15] R. Singh, J. Hunter, A. Philip, The rapid resolution of depression and anxiety symptoms after lower limb amputation, Clin Rehabil 21 (8) (2007) 754–759.
- [16] D.R. Camidge, D.L. Stockton, S. Frame, R. Wood, M. Bain, D.N. Bateman, Hospital admissions and deaths relating to deliberate self-harm and accidents

within 5 years of a cancer diagnosis: a national study in Scotland, UK, Br. J. Cancer 96 (5) (2007) 752–757.

- [17] Surveillance Epidemiology and End Results (SEER) Program: Overview of the SEER Program (5 August 2020).
- [18] W.N. Koepsell TD, Epidemiologic Methods: Studying the Occurrence of Illness 2003 Oxford University Press New York, NY.
- [19] Francesca De Felice, Pierre Blanchard, Radiation-induced neurocognitive dysfunction in head and neck cancer patients, Tumori 103 (4) (2017) 319–324.
- [20] Hui K. Gan, Lori J. Bernstein, Jennifer Brown, Jolie Ringash, Mehrdad Vakilha, Lisa Wang, David Goldstein, John Kim, Andrew Hope, Brian O'Sullivan, John Waldron, Albiruni R. Abdul Razak, Eric X. Chen, Lillian L. Siu, Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer, Int. J. Radiat. Oncol. Biol. Phys. 81 (1) (2011) 126–134.
- [21] Meera Hameed, Howard Dorfman, Primary malignant bone tumors-recent developments, Semin. Diagn. Pathol. 28 (1) (2011) 86–101.
- [22] G.L. Farfalli, J.I. Albergo, L.E. Ritacco, M.A. Ayerza, D.L. Muscolo, L.A. Aponte-Tinao, Oncologic and clinical outcomes in pelvic primary bone sarcomas treated with limb salvage surgery, Musculoskelet. Surg. 99 (3) (2015) 237– 242.
- [23] R.J. Wilson, T.H. Freeman, Jr., J.L. Halpern, H.S. Schwartz, G.E. Holt, Surgical outcomes after limb-sparing resection and reconstruction for pelvic sarcoma: a systematic review, JBJS Rev. 6(4) (2018) e10.
- [24] B.L. Siracuse, G. Gorgy, J. Ruskin, K.S. Beebe, What is the incidence of suicide in patients with bone and soft tissue cancer?: Suicide and sarcoma, Clin. Orthop. Relat. Res. 475 (5) (2017) 1439–1445.
- [25] Leo Kager, Gevorg Tamamyan, Stefan Bielack, Novel insights and therapeutic interventions for pediatric osteosarcoma, Future Oncol. 13 (4) (2017) 357–368.
- [26] R. Bhatia, V. Beckles, Z. Fox, R. Tirabosco, K. Rezajooi, A.T. Casey, Osteosarcoma of the spine: dismal past, any hope for the future?, Br. J. Neurosurg. 28 (4) (2014) 495–502.
- [27] P. Leah, A. Dower, C. Vescovi, M. Mulcahy, D. Al Khawaja, Clinical experience of intracranial chordoma – a systematic review and meta-analysis of the literature, J. Clin. Neurosci. 53 (2018) 6–12.
- [28] T. D'Amore, B. Boyce, A. Mesfin, Chordoma of the mobile spine and sacrum: clinical management and prognosis, J. Spine Surg. 4 (3) (2018) 546–552.
- [29] Paula H. Song, Hadi Beyhaghi, Josh Sommer, Antonia V. Bennett, Symptom burden and life challenges reported by adult chordoma patients and their caregivers, Qual. Life Res. 26 (8) (2017) 2237–2244.
- [30] M. Åkhtar Anwar, Chirine Èl-Baba, Muhammed H. Elnaggar, Yasmeen O. Elkholy, Mohamed Mottawea, Dina Johar, Tuqa S. Al Shehabi, Firas Kobeissy, Charbel Moussalem, Elie Massaad, Ibrahim Omeis, Nadine Darwiche, A.H. Eid, Novel therapeutic strategies for spinal osteosarcomas, Semin. Cancer Biol. 64 (2020) 83–92.
- [31] Daisuke Miyawaki, Masao Murakami, Yusuke Demizu, Ryohei Sasaki, Yasue Niwa, Kazuki Terashima, Hideki Nishimura, Yoshio Hishikawa, Kazuro Sugimura, Brain injury after proton therapy or carbon ion therapy for headand-neck cancer and skull base tumors, Int. J. Radiat. Oncol. Biol. Phys. 75 (2) (2009) 378–384.
- [32] H. Zhou, W. Xian, Y. Zhang, Y. Yang, W. Fang, J. Liu, J. Shen, Z. Zhang, S. Hong, Y. Huang, L. Zhang, Suicide among cancer patients: adolescents and young adult (AYA) versus all-age patients, Ann. Transl. Med. 7 (22) (2019) 658.
- [33] S.B. Bass, S.B. Ruzek, T.F. Gordon, L. Fleisher, N. McKeown-Conn, D. Moore, Relationship of Internet health information use with patient behavior and selfefficacy: experiences of newly diagnosed cancer patients who contact the National Cancer Institute's Cancer Information Service, J. Health Commun. 11 (2) (2006) 219–236.
- [34] Joshua D. Schiffman, Eric Csongradi, Lalita K. Suzuki, Internet use among adolescent and young adults (AYA) with cancer, Pediatr. Blood Cancer 51 (3) (2008) 410–415.
- [35] Anthony Penn, Aura Kuperberg, Psychosocial support in adolescents and young adults with cancer, Cancer J. 24 (6) (2018) 321–327.
- [36] Yvonne W. Leung, Madeline Li, Gerald Devins, Camilla Zimmermann, Anne Rydall, Chris Lo, Gary Rodin, Routine screening for suicidal intention in patients with cancer, Psychooncology 22 (11) (2013) 2537–2545.
- [37] Karen J. Coleman, Eric Johnson, Brian K. Ahmedani, Arne Beck, Rebecca C. Rossom, Susan M. Shortreed, Greg E. Simon, Predicting suicide attempts for racial and ethnic groups of patients during routine clinical care, Suicide Life Threat. Behav. 49 (3) (2019) 724–734.
- [38] M. Moreno-Betancur, H. Sadaoui, C. Piffaretti, G. Rey, Survival analysis with multiple causes of death: extending the competing risks model, Epidemiology 28 (1) (2017) 12–19.
- [39] Asha Z. Ivey-Stephenson, Alex E. Crosby, Shane P.D. Jack, Tadesse Haileyesus, Marcie-jo Kresnow-Sedacca, Suicide trends among and within urbanization levels by sex, race/ethnicity, age group, and mechanism of death – United States, 2001–2015, MMWR Surveill. Summ. 66 (18) (2017) 1–16.
- [40] C.H. Liu, C. Stevens, S.H.M. Wong, M. Yasui, J.A. Chen, The prevalence and predictors of mental health diagnoses and suicide among U.S. college students: implications for addressing disparities in service use, Depress Anxiety 36 (1) (2019) 8-.